ICU Medical (NASDAQ:ICUI) Price Target Raised to $187.00 at Needham & Company LLC

Key Points

• Needham raised ICU Medical’s price target to $187 from $165 and maintained a “buy” rating, implying 12.4% upside from the reported $166.37 share price. The analyst consensus is “Moderate Buy” with an average target of $186.40.
• ICU Medical beat quarterly expectations, reporting $2.37 EPS versus $1.91 expected and $547.9 million in revenue versus $533.4 million forecast. Fiscal 2026 EPS guidance was set at $8.60–$9.00.
• Despite positive earnings and analyst sentiment, valuation remains elevated at roughly 90 times earnings, while revenue grew just 0.5% year over year, leaving investors focused on whether profitability can be sustained.

ICU Medical (NASDAQ:ICUI - Get Free Report) had its price target increased by stock analysts at Needham & Company LLC from $165.00 to $187.00 in a research report issued on Friday,Benzinga reports. The firm currently has a "buy" rating on the medical instruments supplier's stock. Needham & Company LLC's price target would indicate a potential upside of 12.40% from the company's current price.

Other analysts also recently issued reports about the stock. KeyCorp lifted their price target on shares of ICU Medical from $164.00 to $182.00 and gave the company an "overweight" rating in a report on Tuesday, July 21st. Jefferies Financial Group raised shares of ICU Medical to a "strong-buy" rating in a report on Thursday, May 7th. Sanford C. Bernstein lowered shares of ICU Medical to a "market perform" rating in a research report on Monday, June 15th. BTIG Research upped their target price on shares of ICU Medical from $170.00 to $200.00 and gave the company a "buy" rating in a research report on Friday. Finally, Piper Sandler reduced their price objective on ICU Medical from $178.00 to $163.00 and set an "overweight" rating on the stock in a research note on Friday, April 17th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and three have given a Hold rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $186.40.

ICU Medical Trading Down 0.0%

Shares of ICU Medical stock opened at $166.37 on Friday. ICU Medical has a fifty-two week low of $107.00 and a fifty-two week high of $176.27. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.17 and a current ratio of 2.34. The company has a market capitalization of $4.16 billion, a P/E ratio of 89.93, a P/E/G ratio of 2.32 and a beta of 0.74. The company has a fifty day moving average of $150.66 and a 200 day moving average of $140.72.

ICU Medical (NASDAQ:ICUI - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $2.37 earnings per share for the quarter, topping analysts' consensus estimates of $1.91 by $0.46. ICU Medical had a return on equity of 7.50% and a net margin of 2.15%.The firm had revenue of $547.88 million during the quarter, compared to analyst estimates of $533.44 million. During the same quarter in the prior year, the company posted $2.10 earnings per share. The business's quarterly revenue was up .5% compared to the same quarter last year. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. On average, sell-side analysts anticipate that ICU Medical will post 6.51 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other ICU Medical news, VP Virginia Ruth Sanzone sold 2,447 shares of the business's stock in a transaction dated Thursday, May 14th. The shares were sold at an average price of $124.08, for a total value of $303,623.76. Following the completion of the sale, the vice president directly owned 19,460 shares of the company's stock, valued at $2,414,596.80. The trade was a 11.17% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director David C. Greenberg sold 2,424 shares of the firm's stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $122.91, for a total transaction of $297,933.84. Following the transaction, the director directly owned 7,960 shares in the company, valued at approximately $978,363.60. This trade represents a 23.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 2.10% of the company's stock.

Hedge Funds Weigh In On ICU Medical

Hedge funds and other institutional investors have recently made changes to their positions in the company. Millennium Management LLC boosted its position in ICU Medical by 173.4% during the 3rd quarter. Millennium Management LLC now owns 1,089,017 shares of the medical instruments supplier's stock valued at $130,638,000 after acquiring an additional 690,694 shares in the last quarter. Norges Bank purchased a new position in shares of ICU Medical during the fourth quarter worth $58,083,000. Reinhart Partners LLC. purchased a new position in shares of ICU Medical during the 2nd quarter valued at about $46,148,000. Thrivent Financial for Lutherans increased its holdings in shares of ICU Medical by 1,604.0% during the 4th quarter. Thrivent Financial for Lutherans now owns 303,457 shares of the medical instruments supplier's stock valued at $43,294,000 after purchasing an additional 285,648 shares in the last quarter. Finally, UBS Group AG boosted its stake in shares of ICU Medical by 239.8% during the 3rd quarter. UBS Group AG now owns 386,555 shares of the medical instruments supplier's stock worth $46,371,000 after acquiring an additional 272,782 shares in the last quarter. Institutional investors own 96.10% of the company's stock.

ICU Medical News Summary

Here are the key news stories impacting ICU Medical this week:

• Positive Sentiment: Q2 earnings and revenue beat expectations. ICU Medical reported adjusted EPS of $2.37, well above the $1.91 analyst consensus and up from $2.10 a year earlier. Revenue reached $547.9 million versus expectations of $533.4 million. ICU Medical Second-Quarter 2026 Results
• Positive Sentiment: Full-year guidance was raised or reaffirmed above Wall Street expectations. ICU Medical provided fiscal 2026 EPS guidance of $8.60 to $9.00, compared with the consensus estimate of $7.83. The guidance signals stronger anticipated earnings than analysts had previously modeled. Analysts Boost ICU Medical Forecasts
• Positive Sentiment: Analysts increased their price targets. Following the earnings beat and updated outlook, analysts raised their forecasts for ICUI, providing an additional catalyst for the stock and indicating improved confidence in the company’s earnings trajectory. Analyst Price-Target Changes
• Neutral Sentiment: Revenue growth remained limited. Quarterly revenue increased only 0.5% year over year, while the company reported a 2.15% net margin and 7.50% return on equity. Investors may therefore focus on whether earnings growth is sustainable and supported by stronger sales expansion. ICU Medical Q2 Key Metrics
• Negative Sentiment: Valuation remains demanding. With ICUI trading near its 52-week high at roughly 90 times earnings, the stock has limited room for execution disappointments despite the positive earnings news.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source